Research of immunotherapy and splenectomy for chronic liver dysfunction.

慢性肝功能障碍的免疫治疗和脾切除研究。

• 批准号: 16591302
• 负责人: TSUKADA Kazuhiro
• 金额: $ 2.18万
• 依托单位: University of Toyama (2005)Toyama Medical and Pharmaceutical University (2004)
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2004
• 资助国家: 日本
• 起止时间: 2004 至 2005
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-16591302/
• 关键词: Portal hypertension; Splenomegaly; Activated T lymphocyte; 脾腫

1.Making the animal experiment model of portal hypertension and splenomegaly.We tried to make an animal experiment model that was going to reproduce a liver damage, portal hypertension and splenomegaly with a rat experimentally. We used a carbon tetrachloride treated group, a bacillus mort treated group, a bovine serum albumin (BSA) treated group, mitogen treated group, Portocaval shunt (PCS) group, a portal vein ligation county and tested it. It was confirmed that splenomegaly was developed in the group that were ligated the portal vein with two phases.2.Clinical examination in portal hypertension casesWe adjusted lymphocyte from blood and spleen of portal hypertension patients that were performed splenectomy operation. And we analyzed the lymphocyte about expression of CD25,CD26,CD69,CD70 which was an activation marker by using the flowcyte meter. As a result, there were more activated T lymphocytes existed in preoperative blood of portal hypertension case, in comparison with control. In addition, a ratio of an early phase activated T lymphocyte was high in the extracted spleen. After operation, the ratio of the activated T lymphocyte of blood fell in transientness, but it increased again from three postoperative day. As a result, it was suggested, an early phase activated T lymphocyte was accumulated to the spleen in the portal hypertension patient, and after maturation, it flowed out into the peripheral blood.

1、门脉高压、脾肿大动物实验模型的制作。我们试图制作一个动物实验模型，用大鼠实验性地重现肝损伤、门脉高压、脾肿大的情况。我们采用四氯化碳治疗组、死亡芽孢杆菌治疗组、牛血清白蛋白（BSA）治疗组、丝裂原治疗组、门腔静脉分流术（PCS）组、门静脉结扎县进行测试。证实门静脉二期结扎组​​出现脾肿大。2.门静脉高压症的临床检查我们对行脾切除手术的门静脉高压症患者的血液和脾脏进行了淋巴细胞的调整。并采用流式细胞仪分析淋巴细胞活化标志物CD25、CD26、CD69、CD70的表达情况。结果，门静脉高压症患者术前血液中存在比对照者更多的活化T淋巴细胞。另外，在提取的脾脏中，早期活化的T淋巴细胞的比例较高。术后血液中活化T淋巴细胞比例短暂下降，但术后三天后再次上升。结果提示，早期活化的T淋巴细胞在门静脉高压症患者的脾脏中积累，成熟后流入外周血。

项目成果

Urinary trypsin inhibitor suppresses surgical stress-facilitated lung metastasis of murine colon 26-L5 carcinoma cells.

• 发表时间: 2005-03
• 期刊: Anticancer research
• 影响因子: 2
• 作者: I. Yoshioka;Yasunori Tsuchiya;Yasushi Aozuka;Y. Onishi;H. Sakurai;K. Koizumi;K. Tsukada;I. Saiki-I.-Saik

大動脈周囲リンパ節および歯肉転移を切除した原発性肝癌の1例

原发性肝癌主动脉周围淋巴结及牙龈转移瘤切除一例

• 发表时间: 2004
• 期刊: 日本臨床外科学会雑誌 65(8)
• 作者: Sakata E;Shirai Y;Yokoyama N;Wakai T;Sakata J;Hatakeyama K.;Tsukada K.;塚田一博;塚田一博;塚田一博;岸本浩史;ABE H.;Yoshioka I.;Horikawa N;Endo M.;吉田徹;田澤賢一;Yoshioka I. et al.;Horikawa N. et al.;Endo M.et al.;ABE H.et al.;塚田一博;Yamagishi F.;Honi K.;Sakai H.;渋谷和人;坂東 正;田澤賢一;坂東 正
• 通讯作者: 坂東 正

Dieulafoy潰瘍様所見を呈した噴門部胃癌の1例.

一例贲门型胃癌，表现为 Dieulafoy 溃疡样表现。

• 发表时间: 2005
• 期刊: Gastroenterological Endoscopy 47(3)
• 作者: Sakata E;Shirai Y;Yokoyama N;Wakai T;Sakata J;Hatakeyama K.;Tsukada K.;塚田一博;塚田一博;塚田一博;岸本浩史
• 通讯作者: 岸本浩史

十二指腸乳頭腺腫の切除後再発に内視鏡的なAPCによる腫瘍燃灼術が奏効した1例

十二指肠乳头状腺瘤切除后复发一例，内镜APC肿瘤消融成功。

• 发表时间: 2004
• 期刊: Gastroenterological Endoscopy 59(9)
• 作者: Sakata E;Shirai Y;Yokoyama N;Wakai T;Sakata J;Hatakeyama K.;Tsukada K.;塚田一博;塚田一博;塚田一博;岸本浩史;ABE H.;Yoshioka I.;Horikawa N;Endo M.;吉田徹;田澤賢一;Yoshioka I. et al.;Horikawa N. et al.;Endo M.et al.;ABE H.et al.;塚田一博;Yamagishi F.;Honi K.;Sakai H.;渋谷和人
• 通讯作者: 渋谷和人

経皮エタノール注入法(PEIT)、TS-1投与が奏効した胃癌術後肝転移の1例

经皮乙醇注射（PEIT）和TS-1给药成功治疗胃癌后肝转移一例

• 发表时间: 2004
• 期刊: 癌と化学療法 31(3)
• 作者: Sakata E;Shirai Y;Yokoyama N;Wakai T;Sakata J;Hatakeyama K.;Tsukada K.;塚田一博;塚田一博;塚田一博;岸本浩史;ABE H.;Yoshioka I.;Horikawa N;Endo M.;吉田徹;田澤賢一;Yoshioka I. et al.;Horikawa N. et al.;Endo M.et al.;ABE H.et al.;塚田一博;Yamagishi F.;Honi K.;Sakai H.;渋谷和人;坂東 正;田澤賢一
• 通讯作者: 田澤賢一